lidocaine has been researched along with piracetam in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Elkamhawy, A; Hassan, AHE; Lee, J; Moon, B; Pae, AN; Park, BG; Park, HM; Park, JE; Ra, H; Roh, EJ | 1 |
| Lantos, J; Sárosi, I; Temes, G; Török, B | 1 |
| Galenko-Iaroshevskiĭ, PA; Khankoeva, AI; Kryzhanovskiĭ, SA; Popov, PB; Turovaia, AIu; Uvarov, AV | 1 |
| Brockmöller, J; Coupez, R; Lochs, H; Roots, I; Thomsen, T; Wittstock, M | 1 |
| Edginton, AN; Willmann, S | 1 |
1 trial(s) available for lidocaine and piracetam
| Article | Year |
|---|---|
Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests.
Topics: Adult; Anticonvulsants; Caffeine; Humans; Kidney Function Tests; Levetiracetam; Lidocaine; Liver Cirrhosis, Alcoholic; Liver Function Tests; Male; Middle Aged; Piracetam; Sorbitol | 2005 |
6 other study(ies) available for lidocaine and piracetam
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Discovery of 1-(3-(benzyloxy)pyridin-2-yl)-3-(2-(piperazin-1-yl)ethyl)urea: A new modulator for amyloid beta-induced mitochondrial dysfunction.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Cells, Cultured; Cyclosporine; Drug Discovery; Hippocampus; Immunosuppressive Agents; Membrane Potential, Mitochondrial; Mice; Mitochondria; Mitochondrial Membrane Transport Proteins; Molecular Docking Simulation; Neurons; Piperazines; Protein Conformation; Urea | 2017 |
Influence of protective drugs on the EEG during short-term transient ischaemia.
Topics: Animals; Dogs; Electroencephalography; Ischemic Attack, Transient; Lidocaine; Phenytoin; Piracetam; Pyridoxine; Thiopental; Verapamil | 1990 |
[Cardioprotective effects of the cyclic derivative of gamma-aminobutyric acid T3-146 during reperfusion].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cats; Electrocardiography; gamma-Aminobutyric Acid; Lidocaine; Male; Myocardial Reperfusion Injury; Piracetam; Rats | 1997 |
Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis.
Topics: Alfentanil; Humans; Levetiracetam; Lidocaine; Liver Cirrhosis; Models, Biological; Piracetam; Theophylline | 2008 |